Nontawong, Nuttakant
Siripongboonsitti, Taweegrit
Tawinprai, Kriangkrai
Boonpratoom, Mana
Krailassiri, Nawin
Boonkhum, Chayaporn
Soonklang, Kamonwan
Poovorawan, Yong
Mahanonda, Nithi
Funding for this research was provided by:
Chulabhorn Royal Academy
Article History
Received: 19 August 2022
Accepted: 8 November 2022
First Online: 19 November 2022
Declarations
:
: This study was approved by the Ethics Committee for Human Research, Chulabhorn Research Institute (EC No.205/2564). All severe COVID-19 patients were informed about the treatment, and all patients had written the consent forms before admission to receive all treatment options that might benefit all severe COVID-19 patients in addition to a standard of care during the outbreak. Specific convalescent plasma consent was not applicable. Our study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. Consent for publication was not applicable.
: The authors declare that they have no financial and non-financial competing interests.